The Dose-response Study of Topically Delivered Halobetasol Propionate Ointment in Normal Skin in Healthy Adult Subjects

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the duration of application of halobetasol propionate 0.05% ointment to be used in a definitive study of bioequivalence of to formulations of this ointment.

Part A: To validate vasoconstrictor assay precision.

Part B: To evaluate the dose response vasoconstriction profile of Ultravate® 0.05% ointment at different dose durations over a short period of time (0.17 - 4 hrs).

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Actavis Inc.
• Treatments: Clobetasol; Halobetasol

Criteria

Inclusion Criteria:

• Subject understands the study, is willing to participate, and gives written informed consent.

• Subject demonstrates adequate vasoconstriction to the screening topical corticosteroid Halobetasol propionate 0.05% Ointment.

• Subject is a non-smoking (minimum of 14 days), male or female, ages of 18 - 65 years, inclusive.

• Subject is within 20% of their ideal body weight as defined by the 1999 Metropolitan Life Insurance Company Height and Weight Tables.

• Subject is judged by the Investigator to be healthy on the basis of pre-study medical history.

• Subjects of child-bearing potential agree to use an acceptable method of birth control during study participation (e.g. abstinence, any prescribed birth control method, double barrier method, Le. condom plus foam, condom plus diaphragm).

• Subject is willing to refrain from excessive consumption of sodium in food or beverage 48hrs before and for the duration of the study.

• Subject is willing to shower using the same soap/cleansers for the duration of the study.

• Subject is willing to follow study restrictions.

Exclusion Criteria:

• Subject has a past or current medical condition that might significantly affect pharmacodynamic response to topical corticosteroids.

• Subject has clinically significant hypertension or circulatory disease.

• Subject is taking any medication on a regular basis that could modulate blood flow (constrictor or dilator), with the exception of any prescribed birth control method and hormone replacement therapy. Examples of such drugs include nitroglycerin, anti-hypertensives, antihistamines, NSAIDs, aspirin, phenylpropanolamine, or phentolamine.

• Subject is planning to use any exclusionary over-the-counter (OTC) medications within 48 hours prior to or throughout the study that could modulate blood.

• Subject has a history of sensitivity/allergy to the ingredients found in the test formulations or has a history of adverse reactions to topical or systemic corticosteroids.

• Subject has a significant history of allergy to soaps, lotions, emollients, creams, ointments, cosmetics, adhesives, or latex.

• Subject has a history of significant skin conditions or disorders, for example, psoriasis, atopic dermatitis, actinic keratosis, etc.

• Subject has an obvious difference In skin color between arms or the presence of a skin condition, scar tissue, tattoo or coloration that would interfere with placement of test sites, their assessments or could compromise the safety of the subject.

• Subject has used topical medications on the ventral forearms within 1 month prior to dosing.

• Subject has used a tobacco product within 14 days of study conduct.

• Subject has a clinically significant history of drug abuse or alcoholism.

• Subject has donated or received blood within 30 days prior to dosing.

• Subject's caffeine intake is greater than 500 mg per day (1 cup of coffee contains approximately 85 mg of caffeine).

• Subject plans consumption of alcohol, or consumption of caffeine within 48 hours of study conduct or throughout the entire dosing and evaluation period of the study.

• (Females only): Subject is pregnant or lactating.

• Subject has participated in another investigational drug, medical device, or biologics study within 30 days prior to dosing.

formed on all females).